Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Anticuerpos Primarios

Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154) (JN902013)

Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)
Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)
Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)
Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)
Precio(USD):
Especificación:
  • 20ug
  • 50ug
  • 100ug
  • 1mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoJN902013
Reactividad de especiesToxoplasma gondii
AplicacionesELISA, WB
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG1
ID de clonSAA2154
Objetivo Major surface antigen p30
Nivel de endotoxinas Please contact with the lab for this information.
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso P13664
RRID Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Antibody (SAA2154) (abinScience Cat# JN902013, RRID:AB_3729523)
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto
Aplicación Dilución
ELISA 1:2000-1:20000
Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Fondo

Major surface antigen p30 (SAG1) is a ~34 kDa protein. Mediates binding to host cells and is especially important for parasite attachment and fitness in IFN-gamma/IFNG-stimulated host cells. May regulate binding between human S100A6 and vimentin (VIM) for cytoskeleton organization during the early stages of invasion into host cells. Promotes TNF secretion in host cells probably by enhancing binding between human VIM and PRKCQ and activating NF-kappa-B pathway. Promotes viability of host cells to satisfy the survival needs of parasites through the interaction with human RACK1.

1. Robinson, SA. et al. (2004) Parasitology 128, 391-6. PMID: 15151144
2. Cohen, O. et al. (2025) Infection and immunity 93, e0001025. PMID: 40607979
3. Zhou, LJ. et al. (2021) iScience 24, 103514. PMID: 34950858
4. Wang, D. et al. (2024) Acta tropica 251, 107112. PMID: 38157925
Nota For research use only.
Imágenes
  • Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)

    SDS-PAGE

    SDS-PAGE for Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)

  • Anti-Toxoplasma gondii SAG1/Major surface antigen p30 Recombinant Antibody (SAA2154)

    Western blot

    Western blot analysis was performed using anti-/ monoclonal antibody at 1ug/mL on various samples.
    Lane 1: recombinant Toxoplasma gondii SAG1/Major surface antigen p30(Catalog No: JN902012)
    Lane 2: negative control
    Lane 3: negative control

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores